A phase 2 clinical trial (NCT04262856) demonstrated that, in chemotherapy-naïve, PD-L1–positive patients with recurrent or metastatic NSCLC, combination therapy with an αTIGIT antibody and an αPD-1/PD-L1 agent significantly improved overall response rate (ORR) and PFS compared with αPD-1/PD-L1 monotherapy (108). The gene discussed is CD274; the disease is non-small cell lung carcinoma.